A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (238 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: evidencemeasurednonabsoluteinadequately
  Phrases that lowered it: healthytabletkgbioavailabilitybody
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 14.9% (raises risk) · Sponsor's track record
• Primary purpose: not given (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 388 (raises risk) · Sponsor's track record
• Minimum age: 21 (lowers risk) · Who can join
• Sponsor's past trials: 760 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports with a death: 25% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Maximum age: 55 (lowers risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550 NCT01277991 · started 2011 · scored riskier than 1% of active trials completed
• Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers NCT01185184 · started 2010 · scored riskier than 1% of active trials completed
• CP-690,550 Pharmacokinetics In Healthy Chinese Subjects NCT01101919 · started 2010 · scored riskier than 4% of active trials completed
• CP-690,550 And Oral Contraception Drug-Drug Interaction Study NCT01137708 · started 2010 · scored riskier than 2% of active trials completed
• Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan NCT00661661 · started 2008 · scored riskier than 62% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.